Join
Live feed
·
PRReleasevia Quantisnow
Instil Bio Inc. logo

ImmuneOnco Announced Preliminary Safety & Efficacy Data from the Clinical Trial Studying IMM2510/AXN-2510, a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in Front-line NSCLC in China

ByQuantisnow·Wall Street's wire, on your screen.
TIL· Instil Bio Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track TIL (Instil Bio Inc.) and more on Quantisnow.